Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib + Temozolomide vs PLD in Recurrent Ovarian Cancer
NCT01113957Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of veliparib in High-Grade Serous Ovarian Carcinoma (HGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2010; status: completed.
02
Drugs
veliparib
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01113957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113957.